

Cytosorbents Corp  
Form 8-K  
November 21, 2012

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): November 21, 2012

CYTOSORBENTS CORPORATION  
(Exact name of registrant as specified in its charter)

Nevada                      000-51038    98-0373793  
(State or other jurisdiction (Commission (IRS Employer  
of incorporation)              File Number) Identification No.)

7 Deer Park Drive, Suite K

Monmouth Junction, New Jersey              08852

(Address of principal executive offices) (Zip Code)

Registrant's telephone number, including area code: (732) 329-8885

N/A

Edgar Filing: Cytosorbents Corp - Form 8-K

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 2.02 Results of Operations and Financial Condition.

On November 21, 2012, CytoSorbents Corporation issued a press release entitled “CytoSorbents Updates Corporate Progress and Third Quarter 2012 Financial Results,” a copy of which is furnished with this Current Report on Form 8-K as Exhibit 99.1.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

Exhibit Number	Description of Exhibit
99.1	Press release dated November 21, 2012 , “CytoSorbents Updates Corporate Progress and Third Quarter 2012 Financial Results.”

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

CytoSorbents Corporation

Date: November 21, 2012 By: /s/ Dr. Phillip P. Chan  
Name: Dr. Phillip P. Chan  
Title: President and CEO